ABUS Company Profile and Key Details

Q: Who are the executives of ABUS?

Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.Sec.Mr. J. Christopher NaftzgerGen. Counsel & Chief Compliance OfficerMr. William H. CollierPres, Chief Executive Officer & DirectorMr. David C. Hastings CPAChief Financial Officer & Chief Accounting OfficerDr. Elizabeth HowardExecutive Vice President, Gen. Counsel, Chief Compliance Officer & Sec.Dr. Michael J. Sofia Ph.D.Chief Scientific OfficerMs. Lisa M. CaperelliVice President of Investor RelationsDr. Gaston Picchio Ph.D.Chief Devel. OfficerMr. Michael J. McElhaughChief Operating Officer & Chief Bus. OfficerDr. Elizabeth Howard J.D., Ph.D.Executive Vice President, Gen. Counsel, Chief Compliance Officer & Sec.Mr. Christopher NaftzgerGen. Counsel & Chief Compliance OfficerDr. Karen Sims M.D., Ph.D.Chief Medical OfficerKaren SimsVice President of Clinical Devel.Mr. J. Christopher Naftzger BA, Esq., J.D.Gen. Counsel & Chief Compliance Officer

NASDAQ : ABUS

Arbutus Biopharma

$5.01

-0.06-1.18%

Open: 4:00 PM

71.67

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Arbutus Biopharma Corp (ABUS) stock declined over -1.18%, trading at $5.01 on NASDAQ, down from the previous close of $5.07. The stock opened at $5.05, fluctuating between $4.99 and $5.06 in the recent session.

Stock Snapshot

5.07

Prev. Close

989.66M

Market Cap

4.985

Day Low

6.04

P/E Ratio

0.83

EPS (TTM)

-0.51

Cash Flow per Share

5.05

Open

197.54M

Number of Shares

5.06

Day High

77.84%

Free Float in %

0.63

Book Value

6.46M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 18, 2026	5.04	5.06	4.98	5.01	6.46M
Sep 17, 2026	5.10	5.10	5.04	5.07	2.72M
Sep 16, 2026	5.06	5.09	5.02	5.05	4.01M
Sep 15, 2026	5.11	5.15	5.03	5.06	4.05M
Sep 14, 2026	5.12	5.16	5.10	5.13	3.8M
Sep 11, 2026	5.17	5.18	5.11	5.12	1.85M
Sep 10, 2026	5.11	5.17	5.10	5.12	2.45M
Sep 09, 2026	5.16	5.23	5.13	5.17	5.5M
Sep 08, 2026	5.10	5.20	5.08	5.18	5.29M
Sep 04, 2026	5.09	5.17	5.09	5.15	5.2M
Sep 03, 2026	5.11	5.15	5.10	5.12	3.23M
Sep 02, 2026	5.10	5.19	5.09	5.10	2.98M
Sep 01, 2026	5.05	5.10	5.05	5.09	2.61M
Aug 31, 2026	5.05	5.11	4.99	5.08	3.56M
Aug 28, 2026	5.15	5.19	5.05	5.07	4.77M
Aug 27, 2026	5.16	5.22	5.14	5.17	3.58M
Aug 26, 2026	5.19	5.23	5.18	5.19	4.59M
Aug 25, 2026	5.25	5.26	5.13	5.20	8.91M
Aug 24, 2026	5.18	5.28	5.17	5.20	18.14M
Aug 21, 2026	5.20	5.45	5.09	5.21	18.05M

Contact Details

Warminster, PA 18974

United States

http://www.arbutusbio.com 267 469 0914

About Company

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Stock Peers

ARGX

-5.45-0.55%

argenx SE$990.32 REGN

-4.6-0.58%

Regeneron Pharmaceuticals, Inc.$784.85 MDGL

-2.88-0.54%

Madrigal Pharmaceuticals, Inc.$531.52 VRTX

-8.00008-1.55%

Vertex Pharmaceuticals Incorporated$508.34 UTHR

-2.64-0.53%

United Therapeutics Corporation$494.63 ONC

-2.62-0.74%

BeOne Medicines AG$350.84 KRYS

-2.08-0.61%

Krystal Biotech, Inc.$336.67 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-11.52-3.71%

Praxis Precision Medicines, Inc.$298.95 LGND

-1.21-0.43%

Ligand Pharmaceuticals Incorporated$283.49

Frequently Asked Questions

What is the current Arbutus Biopharma Corp (ABUS) stock price?

Arbutus Biopharma Corp (NASDAQ: ABUS) stock price is $5.01 in the last trading session. During the trading session, ABUS stock reached the peak price of $5.06 while $4.99 was the lowest point it dropped to. The percentage change in ABUS stock occurred in the recent session was -1.18% while the dollar amount for the price change in ABUS stock was - $0.06.

ABUS's industry and sector of operation?

The NASDAQ listed ABUS is part of Biotechnology industry that operates in the broader Healthcare sector. Arbutus Biopharma Corp designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ABUS?

Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.
Sec.
Mr. J. Christopher Naftzger
Gen. Counsel & Chief Compliance Officer
Mr. William H. Collier
Pres, Chief Executive Officer & Director
Mr. David C. Hastings CPA
Chief Financial Officer & Chief Accounting Officer
Dr. Elizabeth Howard
Executive Vice President, Gen. Counsel, Chief Compliance Officer & Sec.
Dr. Michael J. Sofia Ph.D.
Chief Scientific Officer
Ms. Lisa M. Caperelli
Vice President of Investor Relations
Dr. Gaston Picchio Ph.D.
Chief Devel. Officer
Mr. Michael J. McElhaugh
Chief Operating Officer & Chief Bus. Officer
Dr. Elizabeth Howard J.D., Ph.D.
Executive Vice President, Gen. Counsel, Chief Compliance Officer & Sec.
Mr. Christopher Naftzger
Gen. Counsel & Chief Compliance Officer
Dr. Karen Sims M.D., Ph.D.
Chief Medical Officer
Karen Sims
Vice President of Clinical Devel.
Mr. J. Christopher Naftzger BA, Esq., J.D.
Gen. Counsel & Chief Compliance Officer

How ABUS did perform over past 52-week?

ABUS's closing price is 43.14% higher than its 52-week low of $3.50 where as its distance from 52-week high of $5.45 is -8.07%.

How many employees does ABUS have?

Number of ABUS employees currently stands at 19.

Link for ABUS official website?

Official Website of ABUS is: http://www.arbutusbio.com

How do I contact ABUS?

ABUS could be contacted at phone 267 469 0914 and can also be accessed through its website. ABUS operates from 701 Veterans Circle, Warminster, PA 18974, United States.

How many shares of ABUS are traded daily?

ABUS stock volume for the day was 6.46M shares. The average number of ABUS shares traded daily for last 3 months was 3.23M.

What is the market cap of ABUS currently?

The market value of ABUS currently stands at $989.66M with its latest stock price at $5.01 and 197.54M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	19
Beta	0.62
Sales or Revenue	$18.14M
5Y Sales Change%	0.025%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	19
Beta	0.62
Sales or Revenue	$18.14M
5Y Sales Change%	0.025%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ABUS Company Profile and Key Details

Arbutus Biopharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Valuation Metrics

Price Forecast & Outlook

Key Takeaways